Hpv Vaccine and Cervical Cancer: is it Worth Vaccinating?

April 24th, 2010 | Author: meilan

Over the past two years, any campaign for Gardasil, the vaccine to protect against new HPV against cervical cancer, has introduced the discussion on the human papilloma virus to the forefront, shining new light not only on the vaccine it itself, but also to the issues surrounding it. HPV is ubiquitous. Nearly 50% of sexually active people will become infected with HPV at some point in their lives. There are about 20 million people with HPV infections in the United States, with 6 2 million new cases each year. The most serious consequence of HPV infections is cancer of the cervix, but public knowledge of HPV is low - less than 50% of women had heard of HPV and its links to cervical cancer uterus. It is essential that the public gains more knowledge about HPV and cancer of the cervix, especially in the current climate where the merits of the vaccine have been clouded by political rhetoric. Information about the link between HPV and cancer of the cervix, the extent of the disease is and who he is, detection methods have different effects of the disease and the role and effectiveness of the vaccine process. Consideration of these questions will help guide decisions that doctors recommend this vaccination to a whole generation of 11-12 years girls and boys, perhaps in the future. The relationship between HPV and cancer of the cervix: There is more than 100 types of HPV. About 15 of them are causing “high risk” types, cancer of the cervix. HPV infections are more common in the younger population, with nearly 75% of 15-25 year olds occur. Most HPV infections are “silent” - people who carry the virus in the know, they directly and freely, their sexual partners. The good news is that most of these infections are self limiting , which means that almost 90% of them without their own solution within 24 months of problems. In a minority of people, but infections, or following a high-risk sexual behavior (such as multiple partners and unprotected sex) or weakened immunity because of smoking, stress, and long-term use of certain drugs like steroids.

These factors can lead to infection with HPV and cancer, precancerous cervical lesions. Approximately 99% of cancers of the cervix caused by HPV. HPV infections are necessary but not sufficient on the cable clean cervical cancer. Pap tests and cancer of the cervix: A Pap test detects changes in the cells of the cervix with HPV or other effects if left untreated, can progress to cervical cancer of the uterus. Fortunately, through a program of Pap well organized in the United States, the incidence of cancer of the cervix uteri of 75% over the last 50 years has decreased. Therefore, for women get regular Pap tests, the incidence of cervical cancer of the uterus is small. Currently the United States, approximately 11,000 new cases of cervical cancer develop each year and about 4,000 die from this. Even if one wishes he had not expected to cases of cancer of the cervix, if the number of HPV infections occur each year, compared the relationship between HPV infection low cervical cancer. The American Cancer Society, four out of five women who did not die of cervical cancer with a Pap test within the past five years. These figures show that the test Pap very successful in reducing the incidence of cancer of the cervix in this country. The role of vaccines against HPV in the prevention of cervical cancer of the uterus: There are now two vaccines against HPV in the world to protect against the two main types of HPV that cause cancer. Gardasil manufactured by Merck, was available in the U.S. since June 2006. Cervarix is manufactured by GlaxoSmithKline, is expected to be introduced into the U. S in late 2008 or early 2009. Both vaccines target HPV types 16 and 18 that cause most cases of cervical cancer. HPV type 16 caused nearly 50% of all cases of cancer of the cervix and type HPV-18 caused nearly 20% of all cases of cancer of the cervix. Clinical studies have shown that both vaccines prevent 70% of cases of cancer of the cervix uteri, with nearly 100% efficiency. However, it is only if the person has been vaccinated before exposure to virus types 16 and 18. The vaccine’s effectiveness decreases once these viruses to access the organization. Therefore, the CDC, the use of the vaccine to girls between the ages of 11-12 is recommended to perform before their first intercourse with a maximum benefit. Pap test versus HPV vaccine cons: to prevent both Pap tests and vaccination against HPV, cancer of the cervix, but they do so in different ways. The vaccines produce antibodies against the HPV virus to fight before they become even cervix. Therefore, the vaccine prevented the development of HPV-related disease on the cervix. On the other hand, the Pap test detects abnormal changes in the cervix as a result of HPV , a large number of monitoring visits and procedures to require these abnormalities progress in preventing cancer. Most people agree that prevention is better than detection or treatment. Management of abnormal smears only cost 2-3 billion per year in this country. But because the vaccine only protects against 70% of cases of cancer cervix, the Pap test should continue to recognize the remaining 30% of cases of cervical cancer the uterus, which are not covered by the vaccine. It is important to note that, apart from the prevention of cervical cancer of the uterus, the vaccine has also been found useful against many other diseases HPV, and could ultimately reduce the number of medical and emotional illnesses that are helping people. Those who are most at risk of cancer of the cervix in the United States, these categories of persons without access to smear or not received because of the lack of access have, either as a result of the socio-economic status, lack of knowledge or cultural differences. These groups are mainly comprised of women from ethnic minorities and whites in the Appalachians. Therefore, training is oriented towards the general public should not only comprehensive program to prevent cancer of the cervix uteri in legal terms but also culturally sensitive must meet the needs of people from different backgrounds. The vaccine against HPV has the potential to save millions of young lives and families, but only if it is the same group of women who have not received their Pap test has now reached, it missed retaining his “less a” promise both here at home and around the world. Shobha S. Krishnan © 2008, MD Author Bio Shobha S. Krishnan, MD, is a consultant gynecologist and dentist at Barnard College, Columbia University. His new book, The HPV vaccine controversy cons: Sex, Cancer, God and politics: A guide for parents, women, men and youth 30 August 2024 by Greenwood Publications. The book presents the latest information about the vaccine without the influence of pharmaceutical companies or other interest groups.

Related items

February 13, 2024 -- Hpv Vaccine and Cervical Cancer: is it Worth Vaccinating? (0)
February 8, 2024 -- Cervical Cancer Vaccine Gardasil (0)
February 8, 2024 -- Cervical Cancer Surgery in India at Special surgery cells of Mumbai (0)
February 8, 2024 -- Cervical Cancer Treatment In India At Affordable Cost (0)
February 8, 2024 -- Exams And Tests For Cervical Cancer (0)
February 6, 2024 -- Cervical Cancer Stages Symptoms (0)
April 23, 2024 -- Cancer Chemotherapy and its side effects (0)
February 14, 2024 -- Controlling Cancer Pain (2)
February 14, 2024 -- Breast Cancer Types (2)
February 13, 2024 -- Breast Cancer Symptoms (9)

beauty and health

Hpv Vaccine and Cervical Cancer: is it Worth Vaccinating?

Related items

Leave a Reply